2496 — Wuhan YZY Biopharma Co Income Statement
0.000.00%
Last trade - 00:00- HK$800.60m
- HK$832.12m
- CNY66.86m
Annual income statement for Wuhan YZY Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 108 | 66.9 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 85.1 | 10.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 134 | 186 | 189 | 201 | 147 |
| Operating Profit | -134 | -186 | -189 | -93.5 | -79.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -149 | -189 | -192 | -97.6 | -84.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -149 | -189 | -192 | -97.6 | -84.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -149 | -189 | -192 | -97.6 | -84.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -149 | -189 | -192 | -97.6 | -84.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.753 | -0.918 | -0.902 | -0.503 | -0.437 |